Craif Co., Ltd.
Craif launches preferential sales of next-generation cancer risk test “MySignal Scan” through Mitsui Sumitomo Aioi Life Insurance’s healthcare service “MSA Care”
……
Craif Co., Ltd. (location: Bunkyo-ku, Tokyo; CEO: Ryuichi Onose; hereinafter referred to as “Craif”) provides the next-generation cancer risk test “MySignal Scan” by Mitsui Sumitomo Aioi Life Insurance Co., Ltd. (location: Central Tokyo) The health care service “MSA Care” of Tokyo Ward, President and CEO: Shiro Kaji, hereinafter referred to as Mitsui Sumitomo Aioi Life Insurance Co., Ltd., will begin offering preferential prices from Friday, December 1, 2023. [Image 1
■About “MSA Care”
We offer a lineup of more than 20 types of pre- and post-coverage services, including early detection of cancer and support for improving lifestyle habits, and many services are available for free. Paid services such as various screening tests are available at preferential prices depending on the user category (*2). In addition, MSA Care’s dedicated website “MSA Care Web Service” provides a new customer experience by providing regular health and medical
information and checking test results (for some services).
*2. To use the service, you must register as a user of “MSA Care Web Service.” ■How to take the “MySignal Scan” test
“MySignal Scan” allows you to check your cancer risk without putting a strain on your body just by collecting urine at home, so even people who don’t have time to go to the hospital or who don’t like going to the hospital can easily undergo the test. can do.
[Image 3